Summary:

- The article discusses the development of an mRNA vaccine for Lyme disease, a tick-borne illness caused by the Borrelia burgdorferi bacteria. This vaccine is being developed by Pfizer and BioNTech, the companies behind one of the COVID-19 mRNA vaccines.

- The article highlights a new study published in the New England Journal of Medicine that shows the vaccine candidate, known as VLA15, was safe and triggered an immune response in a Phase 2 clinical trial. The vaccine targets the outer surface protein A (OspA) of the Borrelia bacteria, which is present in ticks and helps the bacteria survive.

- The article notes that the Lyme disease vaccine faces challenges, including the need for multiple doses and the potential for waning immunity over time. However, the researchers are optimistic that the mRNA platform could lead to a more effective Lyme disease vaccine compared to previous attempts.